Lilly Entered into an Exclusive License Agreement with D. E. Shaw Research to Develop and Commercialize DES-7114 for Immunological and Inflammatory Diseases
Shots:
- DESRES to receive an up front of $60M & is eligible to receive development and commercial milestones of ~$475M along with royalties
- DES-7114 is a highly selective small-molecule inhibitor of the ion channel protein Kv1.3 & has recently completed P-I clinical trials in healthy volunteers. The therapy showed efficacy in preclinical models of multiple chronic inflammatory and autoimmune disease, including UC, CD, & AD
- The utilization of special-purpose supercomputers that have been developed by DESRES to undertake ultra-high-speed, atomically detailed simulations of the three-dimensional motion of physiologically and pharmaceutically relevant molecules enabled the construction of DES-7114
Ref: PRNewswire | Image: Lilly
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
